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Abstract
This paper constructs a doubly robust estimator for continuous dose-response estima-
tion. An outcome regression model is augmented with a set of inverse generalized propen-
sity score covariates to correct for potential misspecification bias. From the augmented
model we can obtain consistent estimates of mean average potential outcomes for distinct
strata of the treatment. A polynomial regression is then fitted to these point estimates to
derive a Taylor approximation to the continuous dose-response function. The bootstrap is
used for variance estimation. Analytical results and simulations show that our approach
can provide a good approximation to linear or nonlinear dose-response functions under
various sources of misspecification of the outcome regression or propensity score models.
Efficiency in finite samples is good relative to minimum variance consistent estimators.
Keywords: Continuous treatments; Dose Response; Doubly robust; Propensity Score.
1 Introduction
The typical set up in causal inference problems is one in which the data available for estimation
are realisations of a random vector, Zi = (Yi,Di,Xi), i = 1, ...,n, where for the i-th unit of
observation Yi denotes a response, Di the treatment received, and Xi a vector of pre-treatment
covariates. The objective is to estimate an average treatment effect (ATE), or in other words,
the difference in response that would occur under different treatment assignments averaged
over the population. However, since the treatment is usually not assigned randomly, simple
comparisons of mean responses across different treatment groups will not in general reveal a
‘causal’ effect due to confounding.
Consistent causal estimates of ATEs can, however, be obtained if the vector of covariates Xi is
sufficient to ensure conditional independence of potential outcomes and treatment assignment.
Using the notation of Tsiatis and Davidian (2007), we write joint densities of the observed
data in the form
fZ(z) = fY |D,X(yi|di,xi)fD|X(di|xi)fX(xi).
Well known causal ATE estimators can be derived via an outcome regression (OR) model
for E(Yi|Di,Xi), the mean of the conditional density of the response given the covariates and
treatment status; or via a propensity score (PS) model, pi(Di|Xi), for the treatment assignment
(or exposure) mechanism.
Doubly robust (DR) estimators combine the OR and PS models, usually by weighting or
augmenting the OR model with covariates derived from the inverse propensity score, to
obtain estimates of ATEs that are consistent and asymptotically normal when either the
OR or the PS model are correctly specified. DR estimators been studied extensively in the
context of binary treatments (e.g. Robins 2000, Robins et al. 2000, Robins and Rotnitzky
2001, van der Laan and Robins 2003, Lunceford and Davidian 2004, Bang and Robins 2005,
Kang and Schafer 2007).
In this paper we extend the binary DR augmented regression approach of Scharfstein et al.
(1999) to derive a Taylor approximation for continuous dose-response functions. We present
theoretical results which explain the DR properties of our approach and simulation results
which show that the estimator can be used to recover a good approximation to linear or
nonlinear dose-response functions.
The paper is structured as follows. Section two explains some general principles of PS based
continuous dose-response estimation. Section three presents our DR model for continuous
treatments and demonstrates the consistency properties of this estimator. Simulation results
are presented in section four. Conclusions are drawn in the final section.
2 Potential outcomes and dose-response estimation for contin-
uous treatments
Throughout the paper we use the convention of upper-case to denote a random variable and
lower case for its observed value. In the single time-point setting, let d ∈ D ⊆ R, denote a
given value (dose) of treatment and let di denote the value of the treatment actually assigned
to unit i. For each unit i let there be a potential outcome Yi(d) associated with each dose,
such that Yi = {Yi(d) : d ∈ D} denotes the full set of potential outcomes. In the data we
observe random variables describing the actual dose received Di, the outcome associated with
that dose Yi(Di), and a set of pre-treatment covariates Xi. We define the indicator for receipt
of dose d as
Id(Di) =
{
1 if Di = d
0 if Di 6= d
,
and similarly the indicator for receipt of the dose actually received is Idi(Di). We assume
that the relationship between actual and potential outcomes obeys the stable unit treatment
value assumption (SUTVA) such that Yi ≡ Id(Di)Yi(d) for all d ∈ D, for all Yi(d) ∈ Yi, and
for i = 1, ...,n.
Our starting point for the analysis of continuous treatments within a potential outcomes
framework is the assumption of weak conditional independence introduced by Imbens (2000),
which requires that Yi(d) ⊥ Id(Di)|Xi for all d ∈ D. If weak conditional independence holds
we can obtain causal estimates from the observed data without knowledge of the full range of
potential outcomes because
E [Yi(d)|Xi] = E [Yi(d)|Id(Di),Xi] = E [Yi|Id(Di),Xi] , (1)
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and taking the expectation over covariates Xi gives the Average Potential Outcome (APO)
at dose d, µ(d) = E [Yi(d)], commonly referred to as the dose-response function.
An OR based approach could be used to estimate (1) by specifying a mean response model
E(Yi|Di,Xi) = Ψ
−1{m(Di,Xi;β)}, for some regression function m() with known link function
Ψ and unknown parameter vector β. If the assumed model provides a correct specification of
the true mean response then in principle a consistent estimate of the dose-response at dose d
can then be obtained using
µ̂OR(d) = n
−1
n∑
i=1
Ψ−1
{
m(d,Xi; β̂)
}
, (2)
that is, the average across all data of the predicted values evaluated at Di = d
As in the case of binary treatments, however, estimation of continuous dose-response functions
is often made more tractable by working with a scalar PS rather than the potentially high di-
mensional covariate vector. For continuous treatments, Imbens (2000) and Hirano and Imbens
(2004) introduce the generalized propensity score (GPS). Let r(d,xi) = fD|X(d|xi) denote
the conditional density function for receiving a particular dose of the treatment given pre-
treatment variables Xi = xi. The observed GPS, which we denote Ri = r(Di,Xi), is a random
variable comprising values from this conditional density evaluated at the level of treatment
actually received (i.e. Di) given Xi = x. In addition, we also define the family of random
variables indexed by d, Rd,i = r(d,Xi), as values from the conditional density of receiving a
particular dose d given Xi. Clearly when Di = d, Ri = Rd,i.
Hirano and Imbens (2004) show that the GPS provides a bias removal strategy in the context
of continuous treatments such that
µ(d) ≡ E[Yi(d)] ≡ EX [E(Yi(d)|X)] = EX [E[Yi(d)|r(d,Xi)]] = EX [E[Yi|Id(Di), r(d,Xi)]]. (3)
Dose response estimation can therefore proceed via OR or GPS based models. The consistency
of the estimator (2) relies on correct specification of an OR model while that of (3) relies on
correct specification of the GPS. In the next section, we develop a DR estimator for continuous
and potentially nonlinear dose-response functions by extending the DR approach for binary
treatments of Scharfstein et al. (1999).
3 Doubly robust estimation for continuous treatments
Dose-response estimation is challenging because the relationship may be nonlinear and the
bias induced by sources of misspecification non-constant across doses. In constructing an
appropriate dose-response estimator, flexibility is required to address the inherent trade off
between fidelity to these nonlinearities and consistency of the estimated causal quantities.
Our proposed approach involves two main steps. First we specify an augmented OR model
to obtain consistent DR estimates of mean APOs for strata of the treatment. We then use
polynomial regression to recover point estimates of the dose-response curve with standard
errors calculated via the bootstrap.
3
3.1 Estimating equations for DR mean APO estimation
In the first step, our estimand of interest is the mean APO for strata of the treatment. We
proceed as follows:
(i) We define Q, q = (1, ...,Q), strata over the range of d and use Dq to denote treatment
stratum q (Dq ⊂ D ⊆ R). We index distinct treatment levels within each stratum by
j = (1, ...,J), such that individual elements of Dq are denoted dqj. Our objective is to
estimate
µ (Dq) = Ej [E {Yi(dqj)}] . (4)
(ii) Given some assumed density, fD|X(d|xi,α), with parameters vector α, and for some
small δ defined around the dose of interest, we define a probability representation of the
GPS as
pi(d|Xi;α) = Pr(d− δ ≤ Di ≤ d+ δ|Xi,α) (5)
=
∫ d+δ
d−δ
fD|X(t|xi,α)dt
= E [Id(Di)|Xi = x] ,
which we refer to as the probabilistic generalized propensity score (PGPS).
(iii) Specifying an appropriate regression model for fD|X(d|xi,α), we use observed doses di
and observed covariates xi to obtain consistent estimates of α̂ and calculate observed
PGPSs: pi(Di|Xi; α̂).
(iv) Denoting membership of treatment stratum q using the indicator Iq(Di), we specify an
augmented OR (AOR) model as
e {Di,Xi, κ̂i(Di,Xi); ξ} = Ψ
−1
m (Di,Xi;β) +
Q∑
q=1
ϕqIq(Di)
pi(Di|Xi; α̂)
 = Ψ−1 {m (Di,Xi, κ̂i(Di,Xi); ξ)}
(6)
say, where ϕ = (ϕ1, ...,ϕQ) is a Q dimensional parameter vector for the inverse PGPS
covariates, ξ = (β,ϕ), and κ̂i(Di,Xi) is an (n×Q) matrix each column of which contains
a covariate for treatment stratum q
Iq(Di)
pi(Di|Xi; α̂)
.
We obtain estimates of ξ = (β,ϕ) as solutions to estimating equations of the form
n∑
i=1
1
φ
∂e {di,xi, κ̂i(di,xi); ξ}
∂ξT
[yi − e {di,xi, κ̂i(di,xi; ξ)}] = 0 (7)
where φ is a working variance matrix for Var[Yi|Di,Xi,κi(Di,Xi)].
(v) For each stratum, we then calculate the means of the predicted values of the AOR model
evaluated at each level of Dq. Our estimator is the average of these means
µ̂DR (Dq) =
1
J
J∑
j=1
[
1
n
n∑
i=1
Ψ−1
{
m
(
dqj ,Xi; β̂
)
+
ϕq
pi(dqj |Xi; α̂)
}]
. (8)
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(vi) Finally, we slide the partition to define new strata and repeat steps (i) to (v) thus
increasing coverage of mean APOs on the dose-response function.
For valid inference, the calculations must be based on a defined region of dose, C ⊆ D,
within which there is common support by treatment status in the covariate distributions. The
common support requirement is met when for any subset of C, say A ⊆ C, Pr(d ∈ A|Xi =
x) > 0 for all d and x and A ⊆ C.
The estimator is doubly robust in the sense that it yields a consistent estimate of the mean
APO in each stratum if one of two parametric restrictions hold: 1) the ORmodel Ψ−1{m(Xi,Di; ξ̂)}
provides an consistent estimate of the true conditional expectation E(Yi|Di,Xi), or; 2) pi(d|Xi; α̂)
provides a consistent estimator of the true PGPS E [Id(Di)|Xi = x]. These restrictions, and
their implications for mean APO estimation, are described in the following two theorems on
redundant conditioning and bias correction.
Theorem 1. (Effects of redundant conditioning on APO estimation). If the OR model
Ψ−1{m(Xi,Di; β̂)} provides a consistent estimate of E[Yi|Di,Xi], then the mean of the pre-
dicted values from this model evaluated at Di = d will provide a consistent estimate of E[Yi(d)]
provided conditional independence between treatment status and response holds. The mean pre-
dicted values from the AOR model, evaluated at Di = d, will also produce a consistent estimate
of E[Yi(d)] under conditional independence, but the AOR model will be less efficient.
Proof. The true conditional expectation to be estimated is E[Yi|Di,Xi], but instead we esti-
mate a model for E [Yi|Di,Xi, κ̂i(Di,Xi)]. If we have conditional independence given covariates
Xi, and if the SUTVA holds, then
E[Yi(d)|Xi, κ̂i(Di,Xi)] = E[Yi|d,Xi, κ̂i(Di,Xi)],
regardless of redundant conditioning on κ̂i(Di,Xi). The dose-response can then be obtained
by taking expectations
E[Yi(d)] = EXi,κ̂i(Di,Xi)[E[Yi|d,Xi, κ̂i(Di,Xi)]] = EXi [E[Yi|d,Xi]].
However, the AOR model will have higher variance than the OR model because
Var (E [Yi(d)|Xi, κ̂i(Di,Xi)]) =Var (E [E [Yi(d)|Xi, κ̂i(Di,Xi)] |κ̂i(Di,Xi)])
+ E [Var (E [Yi(d)|Xi, κ̂i(Di,Xi)] |κ̂i(Di,Xi))]
=Var (E [Yi(d)|Xi]) + E [Var (E [Yi(d)|Xi, κ̂i(Di,Xi)] |κ̂i(Di,Xi))]
and since E [Var (E [Yi(d)|Xi, κ̂i(Di,Xi)] |κ̂i(Di,Xi))] ≥ 0, then Var (E[Yi(d)|Xi, κ̂i(Di,Xi))] ≥
Var (E[Yi(d)|Xi]).
Theorem 2. (The bias correction property). If the estimated propensity score pi(d|Xi; α̂)
provides a consistent estimate of the true propensity score pi(d|Xi; α̂) = E [Id(Di)|Xi = x],
then the mean predicted values from the AOR model, averaged within some stratum of the
treatment, will provide consistent estimates of the mean APO for that stratum, µ (Dq), under
misspecification of the OR model.
Proof. Parameter estimates ϕ̂ are obtained from the AOR model as solution to estimating
equations of the form
n−1
n∑
i=1
Iq(Di)
pii(Di|Xi; α̂)
·
yi −Ψ−1
m (di,xi;β) +
Q∑
q=1
ϕq
Iq(di)
pii(di|xi; α̂)

 = 0,
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which converge in probability to
E
 1
pii(Di|Xi; α̂)
·
Yi −Ψ−1
m (Di,Xi;β) +
Q∑
q=1
ϕq
Iq(Di)
pii(Di|Xi; α̂)

∣∣∣∣Iq(Di) = 1
 .
Writing the AOR model as Ψ−1 {·} and taking expectations over Xi and Di gives
EXi,Di
[
E
(
Idi(Di) ·
1
pii(Di|Xi; α̂)
·
[
Yi −Ψ
−1 {·}
]∣∣∣∣Iq(Di) = 1,Xi,Di)] .
From weak conditional independence and the SUTVA
EXi,Di
[
E [Idi(Di)|Xi] · Iq(Di) · E
(
1
pii(Di|Xi; α̂)
[
Yi(Di)−Ψ
−1 {·}
]∣∣∣∣Iq(Di) = 1,Xi)] ,
and since pii is a function of Xi we use the pull through property to give
EXi,Di
[
E [Idi(Di)|Xi] ·
1
pii(Di|Xi; α̂)
· Iq(Di) · E
(
Yi(Di)−Ψ
−1 {·}
∣∣∣∣Iq(Di) = 1,Xi)] ,
= EXi,Di
[
pii(Di|Xi;α) ·
1
pii(Di|Xi; α̂)
· Iq(Di) · E
(
Yi(Di)−Ψ
−1 {·}
∣∣∣∣Iq(Di) = 1,Xi)]
= EDi
[
E
(
Yi(Di)−Ψ
−1 {·}
∣∣∣∣Iq(Di) = 1)] = 0.
We can write this equation for each stratum q in the form
µ (Dq) = Ej [Ei {Yi(dqj)}] = Ej
[
E
(
Ψ−1
{
m (dqj ,xi;β) +
ϕq
pi(dqj |Xi; α̂
})]
.
Thus, averaging the mean values of the AOR model over dqj ∈ Dq provides an unbiased
estimate of µ (Dq) regardless of whether Ψ
−1
{
m
(
Di,Xi; β̂
)}
is unbiased for E[Yi|Di,Xi].
The estimating equations of the DR model are implied by a number of standard estimators.
For instance, Maximum Likelihood Estimation (MLE), Maximum Quasi-Likelihood (MQL),
Restricted MLE (REML) for linear mixed models (LMMs), and Penalized Quasi-Likelihood
(PQL) for generalized linear mixed models (GLMMs)
3.2 Doubly robust dose-response estimation via Taylor series expansion
The approach outlined above yields consistent estimates of the mean APO for each stratum.
To obtain point estimates on the continuous dose-response function we apply a Taylor series
expansion via a polynomial regression model.
The true dose response function, µ(d) = E [Yi(d)] = f(d; θ) is unknown, but we assume that
it can be well approximated by an Mth degree polynomial function
E [Yi(d)] ≈
M∑
m=0
θmd
m.
The mean APO for stratum q relates to the polynomial dose-response in the following way
Ej {E [Yi(dqj)]} ≈
M∑
m=0
θmEj
(
dmqj
)
,
with sample analogue
µ̂(Dq) =
M∑
m=0
θm
J∑
j=1
dmqj
J
, (9)
where J is the number of units in stratum q. To evaluate this expression we need estimates of
θm. We obtain these by regressing the mean APO estimates for each stratum, µ̂(Dq), onM−1
covariates
∑J
j d
m
qj/J , m = (1, ...,M). Use of OLS will yield best linear unbiased estimates of
θm under the Gauss Markov conditions. We use then use the OLS estimates of θm to recover
a polynomial approximation to points on the dose response function via
µ̂(d) =
M∑
m=0
θ̂md
m.
Variances of the resulting dose-response point estimates can be obtained by applying a single
bootstrap resampling scheme over the estimation of each model component (i.e. PGPS, AOR,
polynomial regression).
3.3 Comparison with existing doubly robust approaches
To our knowledge there are currently only two papers that have constructed DR estimators
using the GPS (van der Laan and Robins 2003, construct a DR estimator for continuous treat-
ments but in the context of marginal structural models and not for point exposure problems).
Flores and Mitnik (2009) combine OR with inverse GPS weighting to obtain a DR weighted
regression estimator for multi-valued, but not continuous treatments, in which doses take
discrete values d = 1, ...k. They do this by weighting the OR model
E[Yi|Di,Xi] =
k∑
j
αj · 11(Di = j) + β
TXi
with weights wi =
√
1/Ri. To calculate a weighted regression (WR) estimator at dose d they
use
µ(d)WR1 =
∑n
i=1
(
α̂d + β̂
Txi
)
· wi∑n
i=1wi
. (10)
They do not provide a formal proof for the DR property but make two arguments for il-
lustration. First, that weighting does not affect the consistency properties of the outcome
regression; and second, that weighting by a correctly specified GPS gives a balanced sample
analogous to adjusting for observed characteristics with experimental data.
Zhang et al. (2012) construct a similar DR estimator for continuous treatments by combining
and OR and a PS model through inverse probability weighting. Their weighted regression
estimator is
µ(d)WR2 =
1
N
N∑
i=1
m(d,Xi, β̂∗), (11)
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where β̂∗ is the estimate for the weighted regression modelm(Di,Xi, β̂∗) with weightsW (Di)/Ri
where W (Di) > 0 is chosen to stabilize the weights when the GPS takes very small values. In
their application they chose W (Di) to be the marginal density of Di under a normal model.
The key difference between our augmented GPS approach, and the GPS weighting approaches,
is that by including multiple inverse GPS covariates for different strata we are able to induce
local rather than global bias correction. This follows from theorem 2 above where we show that
the bias correction is specific to the mean APO for each stratum. If instead we were to employ
a single weighting scheme, or include a single inverse GPS covariate, the bias correction would
be tailored to a mean APO over the whole sample. For non-linear dose response-functions,
local rather than global approximations allow to us to correct for misspecification due to an
inaccurate assumed functional form in addition to effects of confounding. We illustrate these
properties in the simulations presented in the next section.
4 Simulations
The model structure analysed in our simulations corresponds to the following data generating
process.
A continuous treatment is assigned as a function of covariates X1, X2, and Z. The Gaussian
dose-response function is quadratic in the treatment with confounding from X1 and X2.
X1,X2 ∼ N (µX1 = 4,µX2 = 8,σ
2
X1
= 1,σ2X2 = 2, ρ = −0.5)
Z ∼ N (10, 4)
D ∼ N (2.0 + 0.5X1 + 0.25X2 + Z,σ
2
D)
Y ∼ N (1.0 + 4.0D − 0.125D2 + 0.5X1 + 2X2 − 0.5X
2
2 ,σ
2
Y )
The correct OR model is
E[Y |D,X1,X2] = β0 + β1D + β2D
2 + β3X1 + β4X2 + β5X
2
2 ,
and the correct PGPS model is
pi−1T =
∫ D+δ
D−δ
1√
2piσ̂2D
exp
(
−
1
2σ̂2D
(t− µ̂D)
2
)
dt,
where parameters µD and σ
2
D are estimated from the correct regression model
E[D|X1,X2] = α0 + α1X1 + α2X2.
4.1 Simulations for strata mean APO estimation
The following models are tested:
1. µ̂(Dk)OR1 - based on the correctly specified OR model with predicted values averaged
over j = (1, ...,J) treatment levels within each stratum
µ̂OR1(Dk) = J
−1
J∑
j=1
[
n−1
n∑
i=1
Ψ−1
{
m(dkj ,Xi; ξ̂)
}]
.
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2. µ̂(Dk)OR2 - same estimator as µ̂(Dk)OR1 but based on an incorrectly specified OR model,
with X1 assumed as sole confounder.
3. µ̂(Dk)DR1 - a DR estimator as described in equation (8) above based on an incorrectly
specified OR model (X1 as sole confounder) augmented with correctly estimated inverse
PGPS (pi−1T ) covariates for defined strata of the treatment.
4. µ̂(Dk)DR2 - a DR estimator based on a correctly specified OR model augmented with in-
correctly estimated inverse PGPS covariates (pi−1F ), with X1 assumed as sole confounder,
for defined strata of the treatment.
5. µ̂(Dk)DR3 - a DR estimator based on an incorrectly specified OR model augmented with
incorrectly estimated inverse PGPS covariates.
6. µ̂(Dk)DR4 - a DR estimator based on an correctly specified OR model augmented with
correctly estimated inverse PGPS covariates.
The simulations are based on 1000 runs on generated datasets of size 10,000. The mean of d is
16 and the range approximately 1 to 30. Estimates are presented for the following treatment
strata: (10.5,12.5], (12.5,14.5], (14.5,16.5], (16.5,18.5], (18.5,20.5]. To calculate the PGPSs we
set δ = 0.5. Table 1 shows our simulation results. The following results are reported: average
estimates (Av Est), average estimated variances (Av Est Var), empirical variances (Emp Var)
calculated from the bootstrap replications, mean squared error (MSE), and coverage based on
normal bootstrap 95% confidence intervals.
The correctly specified OR model, OR1, provides unbiased estimates of points on the quadratic
dose-response and consequently shows good results for all treatment intervals with relativity
low variance and good coverage. The incorrectly specified OR model, OR2, fails to find
the quadratic relationship between outcome and treatment levels, instead indicating a linear
decreasing effect with poor coverage and large bias and MSE. Augmenting the incorrect OR
model with the inverse PGPS covariates substantially corrects for bias from confounding
and from functional misspecification of the treatment covariate. The DR1 estimator finds
a quadratic relationship between outcome and treatment and performs well in terms of bias,
MSE and coverage, although as we would expect, the variances are larger than for the correctly
specified OR model (which has minimum variance amongst all consistent estimators). The
DR2 model shows that the inclusion of addition irrelevant covariates in the AOR model does
not induce bias, but as illustrated in theorem 1, it does increase the variance relative to the
correct OR model. If the PGPS model and the OR model are wrong there is no DR property
to be had and this is demonstrated in the DR3 results which indicate large bias and variance
in estimation of the dose-response and poor coverage. Finally, if both the PS and the OR
model are correctly specified the doubly robust estimator (DR4) provides unbiased estimates
but with variance larger than would be achieved via a correct OR model alone. Thus, in
summary, the finite sample properties of our DR approach indicate consistent estimation with
relatively good performance in terms of efficiency.
4.2 Simulation of existing doubly robust weighting approaches
Table 2 shows comparative results obtained by fitting the models of equation 10 (WR1) and
equation 11 (WR2). The first thing worth noting is that when the OR model is correctly
specified (DR2 models) both WR models provide consistent estimates, and this is because
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Table 1: Simulation results for Gaussian dose-response GLM with quadratic treat-
ment effect.
treatment intervals
(10.5,12.5] (12.5,14.5] (14.5,16.5] (16.5,18.5] (18.5,20.5]
Truth 15.426 17.176 17.926 17.676 16.426
OR1 Av Est 15.425 17.176 17.926 17.677 16.428
Av Est Var 0.012 0.010 0.010 0.010 0.011
Emp Var 0.011 0.010 0.010 0.010 0.011
MSE 0.012 0.010 0.010 0.010 0.011
Coverage 95.400 95.200 94.800 94.500 95.200
OR2 Av Est 16.944 16.628 16.311 15.994 15.677
Av Est Var 0.025 0.015 0.010 0.012 0.019
Emp Var 0.016 0.007 0.004 0.008 0.019
MSE 2.320 0.308 2.614 2.838 0.579
Coverage 0.000 0.417 0.000 0.000 0.000
DR1 Av Est 15.430 17.177 17.925 17.681 16.428
Av Est Var 0.072 0.046 0.037 0.038 0.050
Emp Var 0.072 0.046 0.037 0.038 0.050
MSE 0.074 0.047 0.040 0.039 0.051
Coverage 94.500 94.400 95.500 94.400 94.900
DR2 Av Est 15.428 17.178 17.926 17.679 16.424
Av Est Var 0.024 0.017 0.016 0.016 0.019
Emp Var 0.024 0.018 0.014 0.016 0.019
MSE 0.024 0.017 0.014 0.016 0.019
Coverage 95.833 94.792 94.792 96.250 94.375
DR3 Av Est 16.162 17.576 18.012 17.439 15.876
Av Est Var 0.072 0.045 0.037 0.040 0.059
Emp Var 0.080 0.043 0.037 0.042 0.062
MSE 0.621 0.203 0.044 0.098 0.365
Coverage 25.833 51.875 91.042 77.708 38.125
DR4 Av Est 15.430 17.172 17.930 17.676 16.422
Av Est Var 0.024 0.018 0.016 0.016 0.020
Emp Var 0.025 0.017 0.016 0.016 0.020
MSE 0.025 0.017 0.016 0.016 0.020
Coverage 94.100 93.000 95.000 94.800 94.800
10
theorem 1 above holds. Note, however, that the variance of the WR1-DR2 estimates is rela-
tively large. When the OR model is incorrectly specified however, the WR estimators based
on a global weighting scheme produce biased estimates of the mean APO for each stratum.
Due to the inclusion of dummies in WR1-DR1 model, a quadratic shape is implied in the
strata estimates, but the global bias correction induced by weighting does not adequately
address local misspecification. With no dummies, as in WR2-DR1, the model fails to find
the quadratic shape of the dose response and again mean APO estimates are biased. Note
that excluding dummies from the WR1 approach we get estimates that are approximately
equivalent to those of WR2.
Table 2: Comparative results based on GPS weighting estimators.
treatment intervals
(10.5,12.5] (12.5,14.5] (14.5,16.5] (16.5,18.5] (18.5,20.5]
Truth 15.426 17.176 17.926 17.676 16.426
WR1-DR1 Av Est 15.854 17.409 17.965 17.561 16.160
Av Est Var 0.068 0.044 0.037 0.039 0.053
Emp Var 0.065 0.044 0.036 0.040 0.056
MSE 0.248 0.098 0.037 0.054 0.127
Coverage 63.750 82.083 95.625 91.458 79.583
WR1-DR2 Av Est 15.420 17.171 17.921 17.665 16.420
Av Est Var 0.023 0.017 0.016 0.016 0.020
Emp Var 0.022 0.017 0.015 0.017 0.019
MSE 0.022 0.017 0.015 0.017 0.019
Coverage 94.792 95.208 95.625 95.625 95.417
WR2-DR1 Av Est 16.700 16.525 16.351 16.176 16.002
Av Est Var 0.012 0.009 0.009 0.011 0.015
Emp Var 0.012 0.010 0.009 0.011 0.015
MSE 1.635 0.433 2.491 2.261 0.196
Coverage 0.000 0.000 0.000 0.000 6.875
WR2-DR2 Av Est 15.420 17.184 17.941 17.692 16.437
Av Est Var 0.012 0.010 0.010 0.010 0.011
Emp Var 0.012 0.011 0.011 0.011 0.012
MSE 0.012 0.011 0.011 0.012 0.012
Coverage 94.700 95.100 95.000 95.300 95.600
4.3 Testing for joint significance of the AOR inverse GPS covariates
In contrast to doubly robust weighting approaches, use of an AOR model allows tests to be
performed on the inclusion of inverse GPS covariates for bias correction. In table 3 below
we present results for Wald Chi-squared tests for the joint significance of the inverse GPS
covariates in our DR simulations.
When the OR model is correctly specified (i.e. DR2 & DR4) the rejection rate of the null
hypothesis (ϕ = 0) is approximately 5% given either a correctly or incorrectly specified GPS
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Table 3: Simulation of Wald Chi-squared tests for joint significance of inverse
GPS covariates, rejections rates for the null: H0 : ϕ = 0 (nominal level is 95%)
H0 rejection rate
DR1 100.0%
DR2 4.7%
DR3 100.0%
DR4 4.8%
model. The size of the test is thus as expected. When the OR model is incorrectly specified
(i.e. DR1 & DR3) the rejection rate of the null is 100%, regardless of whether the GPS model
is correctly specified or not. Thus, while the test shown here cannot provide inference on how
well the GPS covariates have helped to reduce bias from confounding, it can help indicate
when their inclusion offers little beyond an OR specification. This is important, because as
shown above, inclusion of irrelevant covariates in the AOR model can reduce efficiency.
4.4 Simulations for dose-response estimation
We now illustrate how Taylor expansion via polynomial regression can be used to recover an
approximation to the dose-response curve using our mean APO estimates. For the same set up
described above we obtain 1000 simulated set of results for different treatment strata, sliding
the partition of the treatment to increase coverage of mean APOs. We then take the mean
APO estimates for each strata as a response variable and fit a second order polynomial model
to the mean dose as described in section 3 above. The parameters of the polynomial model
are then used to recover an approximation to the dose response.
The results are illustrated graphically in figure 1 which shows the resulting dose-response
curve obtained for DR1 and OR2 estimates relative to the truth. The figure also shows the
mean dose-response curve obtained when the OR2 model is fitted using a Generalised Additive
Model (GAM) (OR2sp), in which case model misspecification arises from confounding rather
than functional misspecification.
The nonparametric fit to the DR1 estimates recovers a good approximation to the true dose-
response curve. The OR2 model finds an incorrect shape for the dose-response because it is
based on biased estimates of the mean APO for each stratum as discussed above. Fitting
the OR2 model semiparametrically, with a smooth term for treatment d, gives a quadratic
dose-response curve but which is still biased due to the effect of confounding from omitted
covariates. This comparison thus demonstrates the ability of the DR model to correct for
misspecification bias arising from both confounding and an incorrect functional form.
5 Conclusions
In this paper we have constructed a doubly robust approach for estimation of dose-response
functions for continuous treatments. The model is doubly robust in the sense that consistent
estimates of average potential outcomes can be obtained for defined strata of the treatment
under misspecification of either the outcome regression or propensity score models. This is
achieved by inducing local bias correction for misspecification of the outcome regression model
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Figure 1: Estimated dose-response functions obtained from fitting second order
polynomial models to the DR1 and OR2 mean APO estimates.
by augmenting it with inverse propensity score covariates corresponding to defined strata of
the treatment. A polynomial regression is then fitted to these point estimates to derive a
Taylor approximation to the continuous dose-response function. Standard errors are derived
by bootstrapping over all model components.
We have shown that our approach can provide a good approximation to linear or nonlinear
dose-response curves and is robust to problems of confounding or functional form misspeci-
fication. Furthermore, simulations show that the efficiency performance in finite samples is
good relative to minimum variance consistent estimators. There are several issues in the pa-
per that require further attention in future research. In particular, the choice of treatment
strata for point estimation could be given a more formal basis. Similarly, the choice of delta
for estimation of propensity score probabilities should be examined in greater depth than has
been possible here.
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